Floatz logo

Evorpacept

HER-2 Protein Overexpression

QuantumLeap Healthcare CollaborativePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the HER-2 Protein Overexpression cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Zanidatamab
Jazz Pharmaceuticals
Phase 2B
Pyrotinib
Tianjin Medical University Second Hospital
Phase 2CCC
Irinotecan
Jin-Hee Ahn
Phase 2CCC
her2 dc1 vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC

View all 18 →

Same molecule, other indications

Evorpacept is also rated in:

breast cancerDormant
B
Indicative ·
60 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
48 / 100
View asset →
composite lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →